Novartis AG (NVS)

89.48
0.01 0.01
NYSE : Health Technology
Prev Close 89.47
Open 90.17
Day Low/High 89.26 / 90.17
52 Wk Low/High 74.97 / 96.31
Volume 1.12M
Avg Volume 2.05M
Exchange NYSE
Shares Outstanding 2.55B
Market Cap 225.86B
EPS 5.50
P/E Ratio 16.63
Div & Yield 1.84 (2.08%)
European Stocks Stabilize as Health Care Gains

European Stocks Stabilize as Health Care Gains

European stocks stabilize on Wednesday, with health care stocks among the gainers as Pfizer reportedly prepares to announce the termination of its $160 billion deal for Allergan.

Fed Worries, Crude Oil Team Up to Beat Down Wall Street

Fed Worries, Crude Oil Team Up to Beat Down Wall Street

Renewed worries over the Federal Reserve's rate hike plans and another selloff in crude oil prices team up to beat down Wall Street in a sour start to the week.

Stocks Extend Drop on Interest Rates Focus

Stocks Extend Drop on Interest Rates Focus

Stocks extend their decline by mid-afternoon Monday on renewed worries the Federal Reserve could raise rates sooner than Wall Street anticipates.

Pfizer Tops List of Best Biopharmaceutical Brands

Pfizer Tops List of Best Biopharmaceutical Brands

Pfizer scored the top spot in Interbrand Health's inaugural ranking of the top 10 biopharmaceutical brands.

Pfizer Tops Interbrand's List of Best Biopharmaceutical Brands

Pfizer Tops Interbrand's List of Best Biopharmaceutical Brands

Pfizer scored the top spot in Interbrand Health's inaugural ranking of the top ten biopharmaceutical brands.

3 Stocks Pushing The Drugs Industry Downward

3 Stocks Pushing The Drugs Industry Downward

TheStreet highlights 3 stocks pushing the drugs industry lower today.

Trade-Ideas: Novartis (NVS) Is Today's Pre-Market Laggard Stock

Trade-Ideas: Novartis (NVS) Is Today's Pre-Market Laggard Stock

Trade-Ideas LLC identified Novartis (NVS) as a pre-market laggard candidate

10 Women Who Would Be a Great Addition to Any Company's Board

10 Women Who Would Be a Great Addition to Any Company's Board

Seven companies in the S&P 500 have no women on their boards. Maybe they're having trouble finding the right women? We aren't. Here are 10 that would make great additions.

Novartis (NVS) Stock Downgraded at Leerink

Novartis (NVS) Stock Downgraded at Leerink

Novartis (NVS) was downgraded to ‘market perform’ from ‘outperform’ at Leerink.

Analysts' Actions -- Alibaba, HollyFrontier, Novartis, Southern Copper and More

Analysts' Actions -- Alibaba, HollyFrontier, Novartis, Southern Copper and More

Here are Wednesday's top research calls, including an upgrade for Alibaba, and downgrades for HollyFrontier, Novartis and Southern Copper.

Novartis (NVS) Down In Early Morning Trading

Novartis (NVS) Down In Early Morning Trading

Trade-Ideas LLC identified Novartis (NVS) as a pre-market laggard candidate

Valeant Looks Like a Choirboy Next to Mallinckrodt, Says Andrew Left

Valeant may have troubles, but Mallinckrodt is the poster child of price gouging.

Incyte Falls on Jakafi Solid-Tumor Setback

Incyte Falls on Jakafi Solid-Tumor Setback

Incyte is halting all clinical trials intended to expand the use of its blood cancer drug Jakafi into solid tumors due to an insufficient level of efficacy.

3 Pharma Stocks to Heal Your Portfolio

Dividend yield is the determining factor in this strategy.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BSMX, COH, DCUA Downgrades: ABR, AIMC, AXP, BANR, BHI, CR, FBP, FTK, IBKC, ISTR, KYO, MOG.A, MOG.B, NVS, NWL, PSMT, RDN, RGS, TCB, TIK, TSLA, VC Initiations: ABCW Read on to get TheStreet Quant Ratings' detailed report:

Exelixis Kidney Cancer Survival Benefit Doesn't Address Competitive Question

Exelixis Kidney Cancer Survival Benefit Doesn't Address Competitive Question

Exelixis didn't provide specifics about the duration of Cometriq's survival benefit, so it's not known if the new data will help the company compete any better against Bristol-Myers Squibb.

Novartis (NVS) Is Weak On High Volume Today

Novartis (NVS) Is Weak On High Volume Today

Trade-Ideas LLC identified Novartis (NVS) as a weak on high relative volume candidate

U.S. Futures Down as Oil Erases Gains; Fed Statement Expected Today

U.S. futures are down ahead of the final day of the Fed's 2-day policy meeting on Wednesday. 

European Stocks Fall Amid Disappointing Earnings

European Stocks Fall Amid Disappointing Earnings

European stocks fall on Wednesday amid a slew of disappointing earnings.

Juno, Kite Valuations at Risk From Simpler T-Cell Cancer Therapy

Juno, Kite Valuations at Risk From Simpler T-Cell Cancer Therapy

Juno and Kite Pharma are under pressure Tuesday after U.S. government researchers published a study showing an off-the-shelf, engineered T-cell therapy could induce remissions in patients with blood cancers.

The Jonas Effect: What to Expect in Post-Blizzard Week Ahead

The Jonas Effect: What to Expect in Post-Blizzard Week Ahead

As Wall Street and the rest of the East Coast recover from a crippling snowstorm, major earnings and economic reports this week will test recent signs of investor optimism.

3 Drugs Stocks Dragging The Industry Down

3 Drugs Stocks Dragging The Industry Down

TheStreet highlights 3 stocks pushing the drugs industry lower today.

As the World Economic Forum Starts in Davos, Watch These 3 Swiss Stocks

The WEF host country has a lot to offer to investors.

Novartis (NVS) Is Today's Pre-Market Laggard Stock

Novartis (NVS) Is Today's Pre-Market Laggard Stock

Trade-Ideas LLC identified Novartis (NVS) as a pre-market laggard candidate

2016 Biotech Stock Prediction: It's Going to Be a Bummer Year, Folks

2016 Biotech Stock Prediction: It's Going to Be a Bummer Year, Folks

I'm only making one big prediction this year: The five-year party which saw biotech stocks outperform the broader markets comes to an end in 2016.

3 European Companies That Offer Big Dividends

3 European Companies That Offer Big Dividends

Europe is emerging this year as a source of unexpectedly, huge opportunity for investors. Here are the three best growth-and-income stocks on the continent.

3 Stocks Pulling The Health Care Sector Downward

3 Stocks Pulling The Health Care Sector Downward

TheStreet highlights 3 stocks pushing the health care sector lower today.

Heavy Trading On Novartis (NVS) Before Market Open

Heavy Trading On Novartis (NVS) Before Market Open

Trade-Ideas LLC identified Novartis (NVS) as a pre-market mover with heavy volume candidate

Feuerstein's Heroes and Zeroes of Biotech Investing in 2015

Feuerstein's Heroes and Zeroes of Biotech Investing in 2015

My biotech and pharma superlatives for 2015.

7 Public Companies That Are Literally Changing People’s Lives

7 Public Companies That Are Literally Changing People’s Lives

These companies are changing people's lives, for the better. It's not just about profits.

TheStreet Quant Rating: A- (Buy)